Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health Outcomes | Injuries/Accidents | Infectious Diseases | Costing Methods | Evidence Synthesis | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
GuidelinesPublication 2012Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Task Force-1
This paper provides an overview of the work of the joint Task Force between the …
This paper provides an overview of the work of the joint Task Force between the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM), provides the overarching recommendations, and discusses future work that is needed. The audience for these papers includes anyone who build models, stakeholders who utilize their results, and those concerned with the use of models to support decision making. This article is part 1 of…
Dynamic Simulation | Microsimulation | Decision Analysis | Health Outcomes | Value of Information | Infectious Diseases | Costing Methods | Mathematical Models | State-Transition | Dynamic Transmission | Calibration/Validation | Health/Medicine -
ReportPublication 2017DCP3: Injury Prevention and Environmental Health
This report from the World Bank is the seventh volume of the Disease Control Priorities, …
This report from the World Bank is the seventh volume of the Disease Control Priorities, Third Edition (DCP3) series and focuses on injury prevention and environmental health. The burden of death and disability resulting from interpersonal violence, road traffic injuries, unintentional injuries, occupational health risks, and climate and pollution falls disproportionately on low- and middle- income countries. This report examines risk factors and offers an economic analysis of platforms to deliver cost-effective interventions to prevent…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health Outcomes | Injuries/Accidents | Costing Methods | Evidence Synthesis | Environmental Health | Policy/Regulation | Global Governance | Climate/Environment | Culture/Society | Economics/Finance | Health/Medicine | Global -
ReportPublication 2015DCP3: Essential Surgery
This report from the World Bank is the first volume of the Disease Control Priorities, …
This report from the World Bank is the first volume of the Disease Control Priorities, Third Edition (DCP3) series. Essential Surgery presents data on the surgical burden of disease, disability, congenital abnormalities, and trauma, as well as the health impact and economic analysis of procedures. This report identifies 44 procedures that address substantial needs, are cost effective, and are feasible to implement in low- and middle-income countries. If made universally available, these 44 procedures could…
Cost-Effectiveness Analysis | Health Outcomes | Injuries/Accidents | Costing Methods | Evidence Synthesis | Health Systems | Global Governance | Clinical Care | Economics/Finance | Health/Medicine | Science/Technology | Global -
ReportPublication 2018Understanding the Economics of Microbial Threats: Proceedings of a Workshop
This report follows a June 2018, Forum on Microbial Threats that was held at the …
This report follows a June 2018, Forum on Microbial Threats that was held at the National Academies of Sciences, Engineering, and Medicine. This was a 1.5-day public workshop with the goal being an assessment of the current understanding of the interaction of infectious disease threats and economic activity in order to suggest future areas of research. This workshop built on prior work of the Forum and aimed to build more mutual understanding between those in…
Technology Assessment | Health Outcomes | Infectious Diseases | Evidence Synthesis | Policy/Regulation | Global Governance | Clinical Care | Business/Industry | Economics/Finance | Health/Medicine | Global -
ReportPublication 2017DCP3: Major Infectious Diseases
This report from the World Bank is the sixth volume of the Disease Control Priorities, …
This report from the World Bank is the sixth volume of the Disease Control Priorities, third edition (DCP3) series and examines the burden of infectious diseases, which remain a leading cause of death globally, especially for children and adolescents. This report identifies feasible and cost-effective platforms to prevent and treat diseases like HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and tropical diseases. This volume also emphasizes the importance of addressing…
Cost-Effectiveness Analysis | Health Outcomes | Infectious Diseases | Costing Methods | Evidence Synthesis | Health Systems | Global Governance | Economics/Finance | Health/Medicine | Global -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Cost-Effectiveness Analysis | Health Outcomes | Infectious Diseases | Costing Methods | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ReportPublication 2022Investment Case for New Tuberculosis Vaccines
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will …
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment. This World Health Organization (WHO) report describes the full value proposition for new TB vaccines. These analyses articulate the broader economic impacts of new TB vaccines to guide global stakeholders when making investment decisions for novel TB vaccines and to plan for…
Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine | Global -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Benefit-Cost Analysis | Infectious Diseases | Preferences/Values | Policy/Regulation | Government/Law | North America